Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer

Fig. 2

Development of an anti-survival factor therapy (ASF therapy).

Development of ASF therapy focuses on the endocrine, growth hormone (GH)-dependent liver-derived, and paracrine, osteoblast-derived, IGF-1 bioavailability that can be abrogated by somatostatin analogs and dexamethasone, respectively. GHRH, GH-releasing hormone IGF-1 = insulin-like growth factor-1; IGFBP-3 = insulin-like growth factor binding protein-3; uPA = urokinase-type plasminogen activator.

Back to article page